Kenvue Inc. $KVUE Stock: Alps Advisors Inc. Grows Stake

Key Points

• Alps Advisors increased its Kenvue stake by 5.7% in the third quarter, adding 90,312 shares to hold 1.67 million shares valued at about $29.4 million. Institutional investors and hedge funds collectively own 97.64% of the stock.
• Kenvue reported quarterly earnings per share of $0.29, matching analyst expectations, while revenue of $3.89 billion topped estimates and rose 3.2% year over year.
• Analysts maintain a consensus Hold rating with a $19.29 price target. Kenvue’s annualized dividend is $0.84 per share, equivalent to a 4.4% yield.

Alps Advisors Inc. boosted its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 5.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,665,764 shares of the company's stock after acquiring an additional 90,312 shares during the period. Alps Advisors Inc. owned 0.09% of Kenvue worth $29,417,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Canvas Wealth Advisors LLC grew its stake in Kenvue by 41.2% during the 3rd quarter. Canvas Wealth Advisors LLC now owns 44,743 shares of the company's stock valued at $875,000 after acquiring an additional 13,066 shares in the last quarter. Alta Advisers Ltd purchased a new stake in shares of Kenvue during the third quarter worth $233,000. Sound Financial Strategies Group LLC purchased a new stake in Kenvue in the third quarter worth about $309,000. Rakuten Investment Management Inc. increased its stake in shares of Kenvue by 9.8% in the 3rd quarter. Rakuten Investment Management Inc. now owns 348,133 shares of the company's stock worth $6,235,000 after purchasing an additional 31,074 shares in the last quarter. Finally, VCI Wealth Management LLC purchased a new position in Kenvue in the 3rd quarter worth about $1,627,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Price Performance

NYSE:KVUE opened at $19.31 on Friday. The firm's 50 day simple moving average is $18.41 and its 200 day simple moving average is $18.24. The company has a market cap of $37.09 billion, a PE ratio of 21.94, a P/E/G ratio of 1.77 and a beta of 0.48. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71. Kenvue Inc. has a one year low of $14.06 and a one year high of $20.13.

Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Friday, October 30th. The company reported $0.29 earnings per share for the quarter, meeting analysts' consensus estimates of $0.29. The business had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.86 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. Kenvue's quarterly revenue was up 3.2% on a year-over-year basis. During the same period last year, the firm posted $0.28 earnings per share. On average, research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 2nd. Investors of record on Monday, September 21st were given a $0.21 dividend. The ex-dividend date of this dividend was Monday, September 21st. This represents a $0.84 dividend on an annualized basis and a dividend yield of 4.4%. Kenvue's dividend payout ratio is 95.45%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on KVUE. Barclays raised their target price on Kenvue from $18.00 to $19.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 21st. UBS Group boosted their price target on Kenvue from $19.00 to $20.00 and gave the company a "neutral" rating in a report on Monday, November 2nd. HSBC lowered their price objective on Kenvue from $20.00 to $19.00 and set a "hold" rating for the company in a research report on Monday, August 10th. Wall Street Zen cut Kenvue from a "buy" rating to a "hold" rating in a report on Saturday, August 8th. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Kenvue in a report on Friday, September 11th. Ten investment analysts have rated the stock with a Hold rating. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $19.29.

Kenvue Profile

Kenvue Inc is a consumer health company that develops and sells products for everyday health and personal care. Its portfolio includes over-the-counter medicines, skin and hair care, oral care, wound care, and baby care products.

Its well-known brands include Tylenol, Neutrogena, Aveeno, Listerine, Band-Aid, Johnson's, and Zyrtec. Kenvue organizes its business around Self Care, Skin Health and Beauty, and Essential Health.

The company became an independent business in 2023 after Johnson & Johnson completed the separation of its consumer health business.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.